To learn more about our prospective biomarker study please click here.
Idylla™ ctEGFR Available Now! Click here for more information

Idylla™ ctBRAF
Mutation Assay (RUO)

Using liquid biopsies for BRAF testing is minimally invasive, fast and easy to perform and provides an excellent solution to study BRAF mutations in different cancer types like lung cancer and melanoma.

Discover the benefits of the Idylla™ ctBRAF Mutation Assay - the easiest and fastest solution to implement liquid biopsy testing in your lab.

The Idylla™ ctBRAF Mutation Assay, performed on the Biocartis Idylla™ System, is a sample-to-result real-time PCR molecular assay for the qualitative detection of V600E/E2/D and V600K/R/M mutations in codon 600 of the BRAF gene. The Idylla™ ctBRAF Mutation Assay extracts and amplifies BRAF circulating tumor DNA (ctDNA) from 1 ml of plasma. Fully automated software interpretation and reporting is also integrated, and provides a result in approx. 90 minutes.

Idylla™ ctBRAF Mutation Assay is for Research Use Only. Not for use in diagnostic procedures.

Request A Demo

Biocartis is recruiting centers for a prospective biomarker study comparing turnaround times of standard of care methods and biomarker testing with Idylla™.

One of the biggest challenges oncology labs face with biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed. For solid biopsies, just one slice of tissue is enough and our plasma-based assays require only 1 ml of plasma.